KR100755577B1 - 타키키닌 수용체 길항제로서의 트리아졸 유도체 - Google Patents

타키키닌 수용체 길항제로서의 트리아졸 유도체 Download PDF

Info

Publication number
KR100755577B1
KR100755577B1 KR1020047017206A KR20047017206A KR100755577B1 KR 100755577 B1 KR100755577 B1 KR 100755577B1 KR 1020047017206 A KR1020047017206 A KR 1020047017206A KR 20047017206 A KR20047017206 A KR 20047017206A KR 100755577 B1 KR100755577 B1 KR 100755577B1
Authority
KR
South Korea
Prior art keywords
phenyl
formula
trifluoromethyl
benzyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047017206A
Other languages
English (en)
Korean (ko)
Other versions
KR20040104634A (ko
Inventor
알버트 쿠쪼비 아메가찌
케빈 매튜 가르디니어
에릭 제임스 헴버
지안 에릭 홍
루이스 니콜라우스 정하임
브라이언 스티븐 뮐
데이비드 마이클 레믹
마이클 알란 로버트슨
케네쓰 알렌 사빈
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20040104634A publication Critical patent/KR20040104634A/ko
Application granted granted Critical
Publication of KR100755577B1 publication Critical patent/KR100755577B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020047017206A 2002-04-26 2003-04-22 타키키닌 수용체 길항제로서의 트리아졸 유도체 Expired - Lifetime KR100755577B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37612102P 2002-04-26 2002-04-26
US60/376,121 2002-04-26
PCT/US2003/010681 WO2003091226A1 (en) 2002-04-26 2003-04-22 Triazole derivatives as tachykinin receptor antagonists

Publications (2)

Publication Number Publication Date
KR20040104634A KR20040104634A (ko) 2004-12-10
KR100755577B1 true KR100755577B1 (ko) 2007-09-12

Family

ID=29270766

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047017206A Expired - Lifetime KR100755577B1 (ko) 2002-04-26 2003-04-22 타키키닌 수용체 길항제로서의 트리아졸 유도체

Country Status (30)

Country Link
US (1) US7320994B2 (enExample)
EP (1) EP1501809B1 (enExample)
JP (1) JP4559087B2 (enExample)
KR (1) KR100755577B1 (enExample)
CN (1) CN1312136C (enExample)
AR (1) AR039329A1 (enExample)
AT (1) ATE384053T1 (enExample)
AU (1) AU2003230829B8 (enExample)
BR (1) BRPI0309534B8 (enExample)
CA (1) CA2483159C (enExample)
CR (1) CR7548A (enExample)
CY (1) CY1107221T1 (enExample)
DE (1) DE60318697T2 (enExample)
DK (1) DK1501809T3 (enExample)
EA (1) EA007720B1 (enExample)
EC (1) ECSP045391A (enExample)
ES (1) ES2298513T3 (enExample)
HR (1) HRP20041008B1 (enExample)
IL (2) IL164675A0 (enExample)
MX (1) MXPA04010622A (enExample)
MY (1) MY141559A (enExample)
NO (1) NO333647B1 (enExample)
NZ (1) NZ535886A (enExample)
PE (1) PE20040600A1 (enExample)
PL (1) PL212090B1 (enExample)
PT (1) PT1501809E (enExample)
TW (1) TWI265807B (enExample)
UA (1) UA79113C2 (enExample)
WO (1) WO2003091226A1 (enExample)
ZA (1) ZA200408670B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
WO2005000821A1 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Tachykinin receptor antagonists
JP4959336B2 (ja) * 2003-10-24 2012-06-20 イーライ リリー アンド カンパニー ｛２−［１−（３，５−ビストリフルオロメチルベンジル）−５−ピリジン−４−イル−１ｈ−［１，２，３］トリアゾル−４−イル］−ピリジン−３−イル｝−（２−クロロフェニル）−メタノンの新規の結晶形態
EP1805142A4 (en) 2004-09-23 2009-06-10 Reddy Us Therapeutics Inc PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
WO2006083711A1 (en) * 2005-02-01 2006-08-10 Eli Lilly And Company Tachykinin receptor antagonists
US7829585B2 (en) 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
US8952176B2 (en) * 2005-06-07 2015-02-10 Shionogi & Co., Ltd. Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
WO2007012579A1 (en) * 2005-07-25 2007-02-01 F. Hoffmann-La Roche Ag Substituted triazole derivatives and their use as neurokinin 3 receptor antagonists
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
AU2006347397A1 (en) * 2006-08-18 2008-02-21 Syngenta Limited Use of HPPD inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
EP2065377B1 (en) 2006-09-21 2011-11-23 Eisai R&D Management Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
BRPI0721069A2 (pt) 2006-12-20 2014-02-04 Lilly Co Eli Intermediários e processo útil na preparação de {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h[1,2, 3]triazol-4-il]-piridin-3-il}-2-clorofenil)-metanona
US8110588B2 (en) 2007-08-08 2012-02-07 Neurosearch A/S 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
JP2011525915A (ja) * 2008-06-26 2011-09-29 アムジエン・インコーポレーテツド キナーゼ阻害薬としてのアルキニルアルコール類
GB0823002D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Isoxazoles derivatives with plant growth regulating properties
US9782397B2 (en) 2011-07-04 2017-10-10 Irbm Science Park S.P.A. Treatment of corneal neovascularization
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
PT3265087T (pt) 2015-03-04 2020-10-15 Vanda Pharmaceuticals Inc Método de tratamento com tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
JP6884801B2 (ja) 2016-05-31 2021-06-09 カルビスタ・ファーマシューティカルズ・リミテッド 血漿カリクレインインヒビターとしてのピラゾール誘導体
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
CN111093671A (zh) 2017-09-13 2020-05-01 万达制药公司 以托吡坦对特应性皮炎的改进治疗
SI3710000T1 (sl) 2017-11-17 2025-07-31 Vanda Pharmaceuticals Inc. Tradipitant za uporabo pri zdravljenju gastropareze
MX2020005168A (es) 2017-11-29 2020-08-20 Kalvista Pharmaceuticals Ltd Formas de dosificacion que contienen un inhibidor calicreina de plasma.
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN111918647A (zh) 2018-02-26 2020-11-10 圣拉斐尔医院有限公司 用于治疗眼痛的nk-1拮抗剂
EP3801514A1 (en) 2018-06-08 2021-04-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
HRP20250097T1 (hr) * 2018-09-28 2025-03-28 Vanda Pharmaceuticals Inc. Primjena tradipitanta kod bolesti kretanja
EP3890735A1 (en) 2018-12-03 2021-10-13 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
IL295327A (en) 2020-02-25 2022-10-01 Vanda Pharmaceuticals Inc Improved treatment of atopic dermatitis with tradipitant
EP4117673A1 (en) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Treatment of stem cell deficiency
US20230145932A1 (en) 2020-03-26 2023-05-11 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
KR20220165251A (ko) 2020-04-03 2022-12-14 네르 쎄라퓨틱스 리미티드 패혈증, 패혈성 쇼크, 급성 호흡 곤란 증후군 (ards) 또는 다발성 기관 기능장애 증후군 (mods)으로부터 선택된 질환을 치료하기 위한 nk-1 수용체 길항제
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
IL298589A (en) 2020-06-02 2023-01-01 Nerre Therapeutics Ltd Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
CN111662235B (zh) * 2020-06-23 2023-12-22 黄淮学院 一种苯甲酰基哒嗪衍生物及其制备方法
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
EP4637766A1 (en) 2022-12-21 2025-10-29 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
CN116082253B (zh) * 2023-02-25 2025-04-25 浙大城市学院 一种1-n-取代的1,2,3-三唑-4-甲酰胺衍生物及其制备方法
WO2024223617A1 (en) * 2023-04-24 2024-10-31 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity
US20250255855A1 (en) 2024-02-09 2025-08-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000068010A (ko) * 1996-07-24 2000-11-25 미리암 디. 메코너헤이, 블레어큐. 퍼거슨 아졸로 트리아진 및 피리미딘

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
WO1995011880A1 (en) * 1993-10-27 1995-05-04 Merck Sharp & Dohme Limited Substituted amides as tachykinin antagonists
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
WO1997040025A1 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Solid phase and combinatorial synthesis of substituted 1,2,3-triazoles and of arrays of substituted 1,2,3-triazoles
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
WO1999007677A1 (en) 1997-08-06 1999-02-18 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
KR20020067548A (ko) * 1999-12-17 2002-08-22 쉐링 코포레이션 선택적인 뉴로키닌 길항제
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
DE10036818A1 (de) * 2000-07-28 2002-02-07 Solvay Pharm Gmbh Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
JP2002123925A (ja) 2000-10-13 2002-04-26 Fuji Photo Film Co Ltd 磁気記録媒体
CN1313450C (zh) * 2002-04-26 2007-05-02 伊莱利利公司 速激肽受体拮抗剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000068010A (ko) * 1996-07-24 2000-11-25 미리암 디. 메코너헤이, 블레어큐. 퍼거슨 아졸로 트리아진 및 피리미딘

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
특허공개 제2000-0068010호

Also Published As

Publication number Publication date
EP1501809B1 (en) 2008-01-16
BRPI0309534B8 (pt) 2021-05-25
CR7548A (es) 2006-12-01
CY1107221T1 (el) 2012-11-21
PL373504A1 (en) 2005-09-05
JP2005536458A (ja) 2005-12-02
AU2003230829B2 (en) 2008-12-04
CA2483159A1 (en) 2003-11-06
BRPI0309534B1 (pt) 2017-11-07
EA007720B1 (ru) 2006-12-29
PE20040600A1 (es) 2004-09-15
KR20040104634A (ko) 2004-12-10
DE60318697T2 (de) 2009-01-08
IL198122A0 (en) 2009-12-24
BR0309534A (pt) 2005-02-01
AU2003230829B8 (en) 2008-12-11
DK1501809T3 (da) 2008-05-13
UA79113C2 (en) 2007-05-25
TWI265807B (en) 2006-11-11
NO333647B1 (no) 2013-07-29
AR039329A1 (es) 2005-02-16
PL212090B1 (pl) 2012-08-31
HRP20041008A2 (en) 2004-12-31
HRP20041008B1 (hr) 2012-10-31
TW200306824A (en) 2003-12-01
WO2003091226A1 (en) 2003-11-06
DE60318697D1 (de) 2008-03-06
IL164675A0 (en) 2005-12-18
EP1501809A1 (en) 2005-02-02
ES2298513T3 (es) 2008-05-16
NZ535886A (en) 2007-07-27
ZA200408670B (en) 2005-10-26
NO20045120L (no) 2004-12-07
HK1073304A1 (en) 2005-09-30
CN1312136C (zh) 2007-04-25
EA200401431A1 (ru) 2005-06-30
CA2483159C (en) 2010-08-10
AU2003230829A1 (en) 2003-11-10
ATE384053T1 (de) 2008-02-15
ECSP045391A (es) 2005-01-03
MXPA04010622A (es) 2005-01-25
CN1646502A (zh) 2005-07-27
US20050239786A1 (en) 2005-10-27
PT1501809E (pt) 2008-03-18
MY141559A (en) 2010-05-14
JP4559087B2 (ja) 2010-10-06
US7320994B2 (en) 2008-01-22

Similar Documents

Publication Publication Date Title
KR100755577B1 (ko) 타키키닌 수용체 길항제로서의 트리아졸 유도체
JP4895476B2 (ja) タキキニン受容体アンタゴニスト
US11168079B2 (en) Alkene compounds as farnesoid x receptor modulators
US11370785B2 (en) Multicyclic compounds as farnesoid X receptor modulators
CZ286498A3 (cs) Chinoxalindiony, způsob a meziprodukty pro jejich výrobu, jejich použití, farmaceutické kompozice na jejich bázi a způsoby léčení
AU2018360575A1 (en) Alkene spirocyclic compounds as farnesoid X receptor modulators
NO332143B1 (no) Imidazolderivater, fremgangsmate for fremstilling av slike, medikament inneholdende slike, slike forbindelser for anvendelse til behandling av sykdom samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdom
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
AU2003224868B8 (en) Tachykinin receptor antagonists
HK1073304B (en) Triazole derivatives as tachykinin receptor antagonists
US20220162201A1 (en) Substituted bicyclic compounds as farnesoid x receptor modulators

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20041025

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20050708

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060721

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20070226

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20060721

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20070529

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20070226

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20070713

Appeal identifier: 2007101005779

Request date: 20070529

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20070529

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20070529

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20061023

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20050708

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20070713

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20070629

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20070829

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20070829

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20100729

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20110728

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20120727

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20120727

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20130812

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20130812

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20140807

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20140807

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20150807

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20150807

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20160811

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20160811

Start annual number: 10

End annual number: 10

PC1801 Expiration of term

Termination date: 20231022

Termination category: Expiration of duration